On October 2, 2025, CytoMed Therapeutics Limited announced research findings in collaboration with The University of Texas, MD Anderson Cancer Center, highlighting their Allogeneic γδ T Cells' potential for treating Acute Myeloid Leukemia. This event is significant for the company and reflects a positive sentiment.